Aflibercept: An update on recent milestones achieved

N. V. Palejwala; A. K. Lauer

doi:10.1358/dot.2014.50.12.2245587

Aflibercept: An update on recent milestones achieved

N. V. Palejwala, A. K. Lauer

Ophthalmology

Research output: Contribution to journal › Article › peer-review

6 Scopus citations

Abstract

In the last decade, intravitreal medications targeted to vascular endothelial growth factor (VEGF) such as pegaptanib, ranibizumab and bevacizumab have revolutionized the treatment and significantly improved visual acuity outcomes in patients with retinal vascular diseases such as age-related macular degeneration (AMD), diabetic macula edema (DME) and retinal vein occlusion (RVO). In recent years, aflibercept, an anti-VEGF drug that targets all isoforms of VEGF as well as placenta growth factor, has shown similar effectiveness in recent clinical trials. Aflibercept has firmly joined ranibizumab and bevacizu - mab as an important therapeutic option in the management of neovascular AMD. More recently, aflibercept appears to be contending with ranibizumab and bevacizumab as an important therapeutic option in the management of DME and RVO.

Original language	English (US)
Pages (from-to)	779-790
Number of pages	12
Journal	Drugs of Today
Volume	50
Issue number	12
DOIs	https://doi.org/10.1358/dot.2014.50.12.2245587
State	Published - Dec 1 2014

Keywords

Aflibercept
Branch retinal vein occlusion
Diabetic macular edema
Eye
Macular edema
Neovascular wet age
Related macular degeneration
VEGF Trap

ASJC Scopus subject areas

Pharmacology
Pharmacology (medical)

Access to Document

10.1358/dot.2014.50.12.2245587

Cite this

@article{bf011b4ef1124b6cb09537b9a38798f7,

title = "Aflibercept: An update on recent milestones achieved",

abstract = "In the last decade, intravitreal medications targeted to vascular endothelial growth factor (VEGF) such as pegaptanib, ranibizumab and bevacizumab have revolutionized the treatment and significantly improved visual acuity outcomes in patients with retinal vascular diseases such as age-related macular degeneration (AMD), diabetic macula edema (DME) and retinal vein occlusion (RVO). In recent years, aflibercept, an anti-VEGF drug that targets all isoforms of VEGF as well as placenta growth factor, has shown similar effectiveness in recent clinical trials. Aflibercept has firmly joined ranibizumab and bevacizu - mab as an important therapeutic option in the management of neovascular AMD. More recently, aflibercept appears to be contending with ranibizumab and bevacizumab as an important therapeutic option in the management of DME and RVO.",

keywords = "Aflibercept, Branch retinal vein occlusion, Diabetic macular edema, Eye, Macular edema, Neovascular wet age, Related macular degeneration, VEGF Trap",

author = "Palejwala, {N. V.} and Lauer, {A. K.}",

year = "2014",

month = dec,

day = "1",

doi = "10.1358/dot.2014.50.12.2245587",

language = "English (US)",

volume = "50",

pages = "779--790",

journal = "Drugs of Today",

issn = "1699-3993",

publisher = "Prous Science",

number = "12",

}

TY - JOUR

T1 - Aflibercept

T2 - An update on recent milestones achieved

AU - Palejwala, N. V.

AU - Lauer, A. K.

PY - 2014/12/1

Y1 - 2014/12/1

N2 - In the last decade, intravitreal medications targeted to vascular endothelial growth factor (VEGF) such as pegaptanib, ranibizumab and bevacizumab have revolutionized the treatment and significantly improved visual acuity outcomes in patients with retinal vascular diseases such as age-related macular degeneration (AMD), diabetic macula edema (DME) and retinal vein occlusion (RVO). In recent years, aflibercept, an anti-VEGF drug that targets all isoforms of VEGF as well as placenta growth factor, has shown similar effectiveness in recent clinical trials. Aflibercept has firmly joined ranibizumab and bevacizu - mab as an important therapeutic option in the management of neovascular AMD. More recently, aflibercept appears to be contending with ranibizumab and bevacizumab as an important therapeutic option in the management of DME and RVO.

AB - In the last decade, intravitreal medications targeted to vascular endothelial growth factor (VEGF) such as pegaptanib, ranibizumab and bevacizumab have revolutionized the treatment and significantly improved visual acuity outcomes in patients with retinal vascular diseases such as age-related macular degeneration (AMD), diabetic macula edema (DME) and retinal vein occlusion (RVO). In recent years, aflibercept, an anti-VEGF drug that targets all isoforms of VEGF as well as placenta growth factor, has shown similar effectiveness in recent clinical trials. Aflibercept has firmly joined ranibizumab and bevacizu - mab as an important therapeutic option in the management of neovascular AMD. More recently, aflibercept appears to be contending with ranibizumab and bevacizumab as an important therapeutic option in the management of DME and RVO.

KW - Aflibercept

KW - Branch retinal vein occlusion

KW - Diabetic macular edema

KW - Eye

KW - Macular edema

KW - Neovascular wet age

KW - Related macular degeneration

KW - VEGF Trap

UR - http://www.scopus.com/inward/record.url?scp=84920028331&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84920028331&partnerID=8YFLogxK

U2 - 10.1358/dot.2014.50.12.2245587

DO - 10.1358/dot.2014.50.12.2245587

M3 - Article

C2 - 25588083

AN - SCOPUS:84920028331

SN - 1699-3993

VL - 50

SP - 779

EP - 790

JO - Drugs of Today

JF - Drugs of Today

IS - 12

ER -

Aflibercept: An update on recent milestones achieved

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this